CD1D Inhibitors

The compounds listed above are not direct inhibitors of CD1d but can modulate its function indirectly by influencing lipid metabolism, antigen presentation, or the interaction of CD1d with NKT cells. CD1d plays a critical role in the immune system by presenting lipid antigens to NKT cells, and alterations in lipid metabolism or CD1d expression can impact this process. Compounds like U18666A and Niemann-Pick C1 Inhibitors affect cholesterol trafficking and lipid storage, respectively, which can alter the repertoire of lipid antigens presented by CD1d. Similarly, β-Sitosterol and Ketoconazole, by influencing lipid metabolism, may modify the types of lipids that CD1d can present.

Statins such as Lovastatin, known for their cholesterol-lowering effects, could indirectly affect the lipid composition associated with CD1d, thereby influencing its function in antigen presentation. Curcumin and Pioglitazone, through their modulation of immune responses and lipid metabolism, respectively, may also impact CD1d's activity. Lipid antigens like Lysophosphatidylcholine, Sulfatide, and α-Galactosylceramide are known to interact with CD1d and can modulate its activity and the subsequent NKT cell response. These compounds are crucial in studying the mechanisms of CD1d-mediated immune responses. Phenylbutyrate and Imiquimod, while having broader effects, may influence CD1d expression and its interaction with NKT cells. These compounds provide additional avenues to explore the regulation of CD1d-mediated antigen presentation and its implications in immune responses.